Labcorp (NYSE:LH) Updates FY 2026 Earnings Guidance

Labcorp (NYSE:LH) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 17.700-18.350 for the period, compared to the consensus earnings per share estimate of 17.760. The company issued revenue guidance of $14.7 billion-$14.8 billion, compared to the consensus revenue estimate of $14.7 billion.

Analysts Set New Price Targets

A number of research firms recently commented on LH. Wall Street Zen lowered Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. JPMorgan Chase & Co. increased their price objective on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Labcorp currently has an average rating of “Moderate Buy” and a consensus price target of $308.00.

Labcorp Stock Down 0.0%

NYSE:LH traded down $0.10 during trading hours on Friday, reaching $256.70. The company had a trading volume of 234,088 shares, compared to its average volume of 684,720. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60. The firm has a market cap of $21.10 billion, a price-to-earnings ratio of 24.60, a P/E/G ratio of 1.76 and a beta of 1.02. The business’s 50-day simple moving average is $270.69 and its two-hundred day simple moving average is $267.48. Labcorp has a twelve month low of $239.67 and a twelve month high of $293.72.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The business had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company posted $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities analysts expect that Labcorp will post 17.67 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is presently 27.53%.

Insider Activity at Labcorp

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the sale, the executive vice president directly owned 2,579 shares in the company, valued at approximately $734,782.89. This trade represents a 17.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jonathan C. Meltzer sold 87 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total transaction of $25,266.54. Following the completion of the sale, the executive vice president owned 2,782 shares of the company’s stock, valued at $807,948.44. The trade was a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 16,113 shares of company stock valued at $4,547,450. Company insiders own 0.84% of the company’s stock.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q1 earnings and revenue beat — Labcorp reported $4.25 EPS vs. $4.09 consensus and revenue of $3.54B (up 5.8% YoY), showing improvement across businesses. Read More.
• Positive Sentiment: Raised FY‑2026 guidance — Labcorp lifted its full‑year profit and revenue outlook (EPS 17.700–18.350; revenue ~$14.7–14.8B), reinforcing forward visibility for the business. That upgrade helped pre‑market strength in the stock. Read More.
• Positive Sentiment: Steady diagnostics demand and segment growth — Management cited steady demand in diagnostics and growth across segments on the call and in press materials, supporting the raised guide and margin dynamics. Read More.
• Neutral Sentiment: Details and color available from the earnings call and transcript — For specifics on drivers (geography, product lines, M&A or cost actions), see the full Q1 earnings call transcript and slide deck. Useful for assessing sustainability of the beat. Read More.
• Neutral Sentiment: Official press release and investor materials posted — Read the company’s release and slide deck for reconciliations and management guidance assumptions. Read More.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. JPL Wealth Management LLC bought a new position in shares of Labcorp in the third quarter valued at $28,000. DV Equities LLC bought a new position in shares of Labcorp in the fourth quarter valued at $29,000. Headlands Technologies LLC lifted its stake in shares of Labcorp by 300.0% in the second quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after buying an additional 96 shares in the last quarter. EFG International AG bought a new position in shares of Labcorp in the fourth quarter valued at $33,000. Finally, Larson Financial Group LLC lifted its stake in shares of Labcorp by 37.5% in the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock valued at $44,000 after buying an additional 42 shares in the last quarter. 95.94% of the stock is owned by institutional investors.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.